BioSpace News Archive

SpecialtyVETPATH, a private, pathologist-owned, and pathologist-directed veterinary pathology laboratory, has selected Proscia®, a leading provider of digital and computational pathology solutions

SOPHiA GENETICS, a cloud-native software company and a leader in data-driven medicine, today announced it will release its financial results for the first quarter of fiscal year 2024 before U.S. markets open on Tuesday, May 7, 2024.

Integrated Biosciences announced a strategic partnership with the patient-led Project 8p Foundation to enhance the treatment landscape for chromosome 8p duplication, deletion and inverted duplication deletion disorders.

SAIL Fusion, a medical device company focused on advancing the surgical treatment of sacroiliac joint dysfunction through solutions built upon proven AO principles, today announced that it has received FDA clearance for its novel BowTie Sacroiliac Fusion System.

Today, Professor Francesco Muntoni, principal investigator of the international multicenter gene therapy trial for Duchenne Muscular Dystrophy with GNT0004 product, sponsored by Genethon, presented the innovative trial design and its initial results at the Myology 2024 international scientific congress, currently taking place in Paris.

The Supervisory Board of Evotec SE has appointed Dr Christian Wojczewski as the Company’s new Chief Executive Officer, effective 01 July 2024.

Day One Biopharmaceuticals, Inc. (Nasdaq: DAWN) (“Day One” or the “Company”) today announced that the U.S. Food and Drug Administration (FDA) has approved OJEMDA (tovorafenib), a type II RAF inhibitor, for the treatment of patients 6 months of age and older with relapsed or refractory pLGG harboring a BRAF fusion or rearrangement, or BRAF V600 mutation.

Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH), a discovery and development stage specialty pharmaceutical company focused on improving the outcomes of cancer patients treated with radiation therapy (“RT”), today announced that its Chief Executive Officer, Dr. Anatoly Dritschilo, will present at the Planet MicroCap Showcase: VEGAS 2024, on Wednesday, May 1, 2024 at 4:30pm PT.

Precision Optics Corporation, Inc. (NASDAQ: POCI), a leading designer and manufacturer of advanced optical instruments for the medical and defense industries, today announced that Dr. Joe Forkey, Chief Executive Officer, and Wayne Coll, Chief Financial Officer, will present at the Planet MicroCap Showcase: VEGAS 2024, on Wednesday, May 1, 2024 at 4:00pm PT.

The global autologous cell therapy market size was evaluated at US$ 7.99 billion in 2023 and is expected to attain around US$ 47.08 billion by 2033, growing at a CAGR of 19.39% from 2024 to 2033.